6996 Stock Overview
A biopharmaceutical company, engages in the development of novel oncology therapies in Greater China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Antengene Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.56 |
| 52 Week High | HK$2.25 |
| 52 Week Low | HK$0.50 |
| Beta | 0.81 |
| 11 Month Change | 0% |
| 3 Month Change | -43.43% |
| 1 Year Change | -58.52% |
| 33 Year Change | -95.66% |
| 5 Year Change | n/a |
| Change since IPO | -96.94% |
Recent News & Updates
Recent updates
Revenues Tell The Story For Antengene Corporation Limited (HKG:6996)
Jan 09
The Price Is Right For Antengene Corporation Limited (HKG:6996) Even After Diving 26%
Sep 20Antengene Corporation Limited (HKG:6996) Analysts Just Slashed This Year's Estimates
Apr 03We're Not Very Worried About Antengene's (HKG:6996) Cash Burn Rate
Feb 19Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth
Nov 05We Think Antengene (HKG:6996) Can Afford To Drive Business Growth
Jun 28We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely
Mar 08We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely
Nov 18Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth
Aug 17Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth
Apr 29What Type Of Shareholders Own The Most Number of Antengene Corporation Limited (HKG:6996) Shares?
Feb 22Shareholder Returns
| 6996 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 1.8% | -4.3% | 2.1% |
| 1Y | -58.5% | 3.1% | 3.4% |
Return vs Industry: 6996 underperformed the Hong Kong Pharmaceuticals industry which returned 5.3% over the past year.
Return vs Market: 6996 underperformed the Hong Kong Market which returned 4.4% over the past year.
Price Volatility
| 6996 volatility | |
|---|---|
| 6996 Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in HK Market | 13.1% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 6996's share price has been volatile over the past 3 months.
Volatility Over Time: 6996's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 178 | Jay Mei | www.antengene.com |
Antengene Corporation Limited, a biopharmaceutical company, engages in the development of novel oncology therapies in Greater China and internationally. The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients in Mainland China, Singapore, Australia, Hong Kong, Macau, and Taiwan. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR kinase inhibitor for the treatment of cervical cancer and other advanced solid tumors.
Antengene Corporation Limited Fundamentals Summary
| 6996 fundamental statistics | |
|---|---|
| Market cap | HK$371.19m |
| Earnings (TTM) | -HK$580.64m |
| Revenue (TTM) | HK$61.48m |
6.1x
P/S Ratio-0.7x
P/E RatioIs 6996 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6996 income statement (TTM) | |
|---|---|
| Revenue | CN¥56.07m |
| Cost of Revenue | CN¥8.50m |
| Gross Profit | CN¥47.57m |
| Other Expenses | CN¥577.09m |
| Earnings | -CN¥529.52m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.78 |
| Gross Margin | 84.84% |
| Net Profit Margin | -944.43% |
| Debt/Equity Ratio | 18.1% |
How did 6996 perform over the long term?
See historical performance and comparison